TY - JOUR
T1 - Long-term outcomes for heart failure patients with and without diabetes
T2 - From the Get With The Guidelines–Heart Failure Registry
AU - Ziaeian, Boback
AU - Hernandez, Adrian F.
AU - DeVore, Adam D.
AU - Wu, Jingjing
AU - Xu, Haolin
AU - Heidenreich, Paul A.
AU - Matsouaka, Roland A.
AU - Bhatt, Deepak L.
AU - Yancy, Clyde W.
AU - Fonarow, Gregg C.
N1 - Funding Information:
Funding: The Get With The Guidelines–Heart Failure (GWTG-HF) program is provided by the American Heart Association (AHA). GWTG-HF is sponsored, in part, by Amgen Cardiovascular and has been funded in the past through support from Medtronic, GlaxoSmithKline, Ortho-McNeil, and the AHA Pharmaceutical Roundtable. B. Ziaeian is supported by the ACC Presidential Career Developmental Award and AHA SDG 17SDG33630113.This project was supported by the American Heart Association's GWTG program and the American College of Cardiology Presidential Career Development award. No person or organization outside of the authors contributed in any substantive way to writing, editing, or statistical analyses reported in this manuscript.
Funding Information:
Funding: The Get With The Guidelines–Heart Failure (GWTG-HF) program is provided by the American Heart Association (AHA). GWTG-HF is sponsored, in part, by Amgen Cardiovascular and has been funded in the past through support from Medtronic, GlaxoSmithKline, Ortho-McNeil, and the AHA Pharmaceutical Roundtable. B. Ziaeian is supported by the ACC Presidential Career Developmental Award and AHA SDG 17SDG33630113 .
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/5
Y1 - 2019/5
N2 - Background: Diabetes mellitus is an increasingly prevalent condition among heart failure (HF) patients. The long-term morbidity and mortality among patients with and without diabetes with HF with reduced (HFrEF), borderline (HFbEF), and preserved ejection fraction (HFpEF) are not well described. Methods: Using the Get With The Guidelines (GWTG)–HF Registry linked to Centers for Medicare & Medicaid Services claims data, we evaluated differences between HF patients with and without diabetes. Adjusted Cox proportional-hazard models controlling for patient and hospital characteristics were used to evaluate mortality and readmission outcomes. Results: A cohort of 86,659 HF patients aged ≥65 years was followed for 3 years from discharge. Unadjusted all-cause mortality was between 4.4% and 5.5% and all-cause hospitalization was between 19.4% and 22.6% for all groups at 30 days. For all-cause mortality at 3 years from hospital discharge, diabetes was associated with an adjusted hazard ratio of 1.27 (95% CI 1.07-1.49, P =.0051) for HFrEF, 0.95 (95% CI 0.55-1.65, P =.8536) for HFbEF, 1.02 (95% CI 0.87-1.19, P =.8551) for HFpEF. For all-cause readmission, diabetes was associated with an adjusted hazard ratio of 1.06 (95% CI 0.87-1.29, P =.5585) for HFrEF, 1.48 (95% CI 1.15-1.90, P =.0023) for HFbEF, and 1.06 (95% CI 0.91-1.22, P =.4747) for HFpEF. Conclusions: HFrEF and HFbEF patients with diabetes are at increased risk for mortality and rehospitalization after hospitalization for HF, independent of other patient and hospital characteristics. Among HFpEF patients, diabetes does not appear to be independently associated with significant additional risks.
AB - Background: Diabetes mellitus is an increasingly prevalent condition among heart failure (HF) patients. The long-term morbidity and mortality among patients with and without diabetes with HF with reduced (HFrEF), borderline (HFbEF), and preserved ejection fraction (HFpEF) are not well described. Methods: Using the Get With The Guidelines (GWTG)–HF Registry linked to Centers for Medicare & Medicaid Services claims data, we evaluated differences between HF patients with and without diabetes. Adjusted Cox proportional-hazard models controlling for patient and hospital characteristics were used to evaluate mortality and readmission outcomes. Results: A cohort of 86,659 HF patients aged ≥65 years was followed for 3 years from discharge. Unadjusted all-cause mortality was between 4.4% and 5.5% and all-cause hospitalization was between 19.4% and 22.6% for all groups at 30 days. For all-cause mortality at 3 years from hospital discharge, diabetes was associated with an adjusted hazard ratio of 1.27 (95% CI 1.07-1.49, P =.0051) for HFrEF, 0.95 (95% CI 0.55-1.65, P =.8536) for HFbEF, 1.02 (95% CI 0.87-1.19, P =.8551) for HFpEF. For all-cause readmission, diabetes was associated with an adjusted hazard ratio of 1.06 (95% CI 0.87-1.29, P =.5585) for HFrEF, 1.48 (95% CI 1.15-1.90, P =.0023) for HFbEF, and 1.06 (95% CI 0.91-1.22, P =.4747) for HFpEF. Conclusions: HFrEF and HFbEF patients with diabetes are at increased risk for mortality and rehospitalization after hospitalization for HF, independent of other patient and hospital characteristics. Among HFpEF patients, diabetes does not appear to be independently associated with significant additional risks.
UR - http://www.scopus.com/inward/record.url?scp=85061981277&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061981277&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2019.01.006
DO - 10.1016/j.ahj.2019.01.006
M3 - Article
C2 - 30818060
AN - SCOPUS:85061981277
SN - 0002-8703
VL - 211
SP - 1
EP - 10
JO - American Heart Journal
JF - American Heart Journal
ER -